Clinical Research Directory
Browse clinical research sites, groups, and studies.
68Ga-NI-FAPI PET/CT: First-in-human Study
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.
Official title: 68Ga-NI-FAPI PET/CT: First-in-human Study in Patients With Various Cancers
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-08-01
Completion Date
2025-12-31
Last Updated
2024-11-14
Healthy Volunteers
No
Conditions
Interventions
68Ga-NI-FAPI
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-NI-FAPI.
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China